nCounter® Autoimmune Discovery Panel
Helping Your Research
The nCounter Autoimmune Discovery Panel is designed to enable researchers to discover links between known autoimmune disease associated germline variants and gene expression. The genes were selected in collaboration with leading autoimmune researchers and are linked to the top nine autoimmune diseases. This panel is made-to-order and you can add on up to 55 gene targets to the panel with the Panel Plus product to customize the panel to your research project.
How it Works
The Human nCounter Autoimmune Discovery Panel is a 770-gene panel that provides analysis of the links between known disease associated mutations and gene expression changes, allowing researchers to identify new gene functions and to look at gene expression in response to treatment. Highlights of the Autoimmune Discovery Panel include:
Discovery tool for disease-associated mutation gene function studies and biomarker characterization
Comprehensive content associated with nine autoimmune diseases
Gene expression profiling of immune response together with gene mutations
Made-to-order & customizable with the Panel Plus option – add up to 55 user-defined genes
Simple workflow, user-friendly, and efficient with just 15 minutes total hands-on time
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
Coverage of Autoimmune Diseases
Disease-specific annotations for nine autoimmune disease types and human immune response genes were assigned across all genes in the autoimmune discovery panel, allowing for the identification of gene functions and signatures for all autoimmune diseases.
Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea.
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitor has been reported to have kidney-protective benefits. To elucidate how antidiabetic agents prevent diabetic kidney disease progression, it is important to investigate their effect on the kidney environment in type 2 diabetes mellitus (DM) patients.
Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives.
Systemic autoinflammatory diseases are a heterogeneous family of disorders characterized by a dysregulation of the innate immune system, in which sterile inflammation primarily develops through antigen-independent hyperactivation of immune pathways. In most cases, they have a strong genetic background, with mutations in single genes involved in inflammation.
Synthetic hookworm-derived peptides are potent modulators of primary human immune cell function that protect against experimental colitis in vivo.
The prevalence of autoimmune diseases is on the rise globally. Currently, autoimmunity presents in over 100 different forms and affects around 9% of the world’s population.